While earlier studies described reduced miR-181 expression in high-risk MDS [15], others reported pro-leukemic activity under certain mutational backgrounds [28], suggesting that miR-181 may contribute to disease evolution via threshold-dependent modulation of differentiation regulators such as BCL2 and MEIS1. Here, BCL2 is linked to myelodysplastic syndrome.